Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Asset Writedowns and Impairment (2016 - 2024)

Historic Asset Writedowns and Impairment for Myriad Genetics (MYGN) over the last 14 years, with Q4 2024 value amounting to $43.0 million.

  • Myriad Genetics' Asset Writedowns and Impairment changed N/A to $43.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year increase of 30735.29%. This contributed to the annual value of $56.6 million for FY2024, which is N/A changed from last year.
  • Per Myriad Genetics' latest filing, its Asset Writedowns and Impairment stood at $43.0 million for Q4 2024.
  • Myriad Genetics' Asset Writedowns and Impairment's 5-year high stood at $98.4 million during Q1 2020, with a 5-year trough of $800000.0 in Q3 2024.
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $8.6 million (2021), whereas its average is $22.3 million.